NASDAQ · AXGN
Healthcare · Medical - Devices
$43.39
Down-$0.03 (-0.07%)
Updated Sep 28, 2026, 10:03 PM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AXGN
1M range · 19 trading sessions · Daily adjusted prices
Prices through Sep 25, 2026
AXGN closed at $43.39 after 19 trading sessions, down 14.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $43.61 | $44.68 | $43.05 | $43.39 | 1.22M |
| Sep 24, 2026 | $43.18 | $43.95 | $42.55 | $43.32 | 796.67K |
| Sep 23, 2026 | $44.54 | $44.84 | $43.25 | $43.32 | 1.25M |
| Sep 22, 2026 | $46.17 | $47.00 | $44.00 | $44.54 | 1.33M |
| Sep 21, 2026 | $44.82 | $46.58 | $44.32 | $45.93 | 1.2M |
| Sep 18, 2026 | $44.94 | $45.66 | $44.16 | $44.23 | 1.12M |
| Sep 17, 2026 | $45.91 | $46.89 | $45.07 | $45.285 | 831.48K |
| Sep 16, 2026 | $44.87 | $46.35 | $44.03 | $45.44 | 1.42M |
| Sep 15, 2026 | $43.85 | $45.46 | $43.51 | $44.97 | 1.4M |
| Sep 14, 2026 | $41.55 | $44.00 | $41.55 | $43.78 | 1.67M |
| Sep 11, 2026 | $42.48 | $42.59 | $39.62 | $42.16 | 3.48M |
| Sep 10, 2026 | $45.135 | $45.50 | $41.74 | $41.85 | 3.79M |
| Sep 9, 2026 | $46.21 | $48.105 | $46.00 | $47.27 | 728.8K |
| Sep 8, 2026 | $47.19 | $47.975 | $46.26 | $46.69 | 541.49K |
| Sep 4, 2026 | $46.73 | $48.385 | $46.29 | $48.28 | 550.07K |
| Sep 3, 2026 | $48.66 | $49.06 | $46.79 | $47.10 | 951.25K |
| Sep 2, 2026 | $50.15 | $51.50 | $47.83 | $48.30 | 789.92K |
| Sep 1, 2026 | $50.64 | $51.00 | $49.29 | $49.88 | 596.57K |
| Aug 31, 2026 | $50.97 | $51.18 | $49.63 | $50.76 | 878.14K |
The latest Smart Investors Daily articles mentioning AXGN.
AXGN research
Company profile and research snapshot.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | Raymond James | Outperform | — |
| Aug 26, 2026 | Truist Securities | Buy | — |
| Jul 30, 2026 | Canaccord Genuity | Buy | — |
| Jul 30, 2026 | Citizens | Market Outperform | — |
| Jul 30, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
Truist Securities analyst Ravi Misra initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $60.
Yahoo · Jul 15, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the con
SeekingAlpha · Mar 6, 2026
Axogen, Inc. (AXGN) 47th Annual Raymond James Institutional Investor Conference March 3, 2026 3:25 PM ESTCompany ParticipantsMichael Dale - President, CEO...
SeekingAlpha · Feb 25, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AXGN.
